Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy
- 7 September 2011
- journal article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 17 (5) , 447-455
Abstract
Although post-mastectomy radiation therapy (PMRT) has shown benefits, its effects in patient subpopulations remain uncertain. Therefore, we assessed whether breast cancer subtype and p53 overexpression were associated with outcome after modified radical mastectomy (MRM), with or without PMRT. We retrospectively analyzed the records of patients who underwent MRM, with or without PMRT, between January 1991 and December 2008. Patients were considered eligible if they had T3 or T4 stage disease; any T stage with N2 or N3 stage; any T or N stage with positive, close (P = 0.029). This trend was evident in the subgroup of luminal type A breast cancer (P = 0.017) and non-p53 overexpression (P = 0.026) patients. However, there was no significant survival benefit from PMRT in the subgroup of triple negative (TN) breast cancer (P = 0.528) and p53 overexpression (P = 0.189) patients. The benefit of PMRT differed among subgroups with different breast cancer subtype and p53 overexpression. More efficacious systemic treatment strategies are needed, especially in patients at high risk for distant metastasis, to obtain optimal therapeutic gain.Keywords
This publication has 27 references indexed in Scilit:
- Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapyOncology Reports, 2010
- Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndromeCurrent Opinion in Oncology, 2010
- Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyBreast Cancer Research, 2009
- Pattern of metastatic spread in triple-negative breast cancerBreast Cancer Research and Treatment, 2008
- Immunohistochemical detection of EGFR, p185erbB-2, Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal womenBiotechnic & Histochemistry, 2008
- Postmastectomy Radiation and Survival in Older Women With Breast CancerJournal of Clinical Oncology, 2006
- Concordance among Gene-Expression–Based Predictors for Breast CancerNew England Journal of Medicine, 2006
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast CancerActa Oncologica, 2000
- Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysisAPMIS, 1997